Scholarlink

Background <p>Pathological T1a-muscularis mucosa with lymphovascular invasion and T1b-submucosa are high-risk factors for lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Esophagectomy and chemoradiotherapy are recommended following endoscopic submucosal dissection (ESD) but can lead to complications. Here, we evaluated the efficacy and safety of chemotherapy following ESD.</p> Methods <p>This prospective and retrospective study included patients with pathological T1a-muscularis mucosa with lymphovascular invasion or T1b-submucosa who underwent esophageal ESD between June 2006 and August 2023, followed by chemotherapy or chemoradiotherapy. The overall survival, cause-specific survival, recurrence-free survival, hospitalization period, and the occurrence of grade ≥ 3 adverse events were compared between the chemotherapy and chemoradiotherapy groups.</p> Results <p>The patient and tumor characteristics and pathological findings did not significantly differ between the chemotherapy (n = 16) and chemoradiotherapy (n = 15) groups. The 5-year overall and recurrence-free survival rates were significantly higher in the chemotherapy group than in the chemoradiotherapy group (100.0% vs. 77.8%,<i> P</i> &lt; 0.001 and 92.3% vs. 84.9%, <i>P</i> = 0.007, respectively; log-rank test). The 5-year cause-specific survival rate did not significantly differ between groups (100.0% vs. 83.3%, <i>P</i> = 0.14, log-rank test). The hospitalization period was significantly shorter in the chemotherapy group than in the chemoradiotherapy group (34 vs. 48&#xa0;days, <i>P</i> &lt; 0.001). Grade ≥ 3 adverse events occurred in 4 (25.0%) and 11 (73.3%) patients in the chemotherapy and chemoradiotherapy groups, respectively.</p> Conclusions <p>Chemotherapy is a safe and effective additional treatment for ESCC (pathological T1a-muscularis mucosa with lymphovascular invasion or T1b-submucosa) after ESD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection

  • 期刊论文

  • 发表日期：

    2025年10月20日

查看全文
  • Yujiro Adachi,
  • Yoshito Hayashi,
  • Shinji Yoneda,
  • Ayaka Tajiri,
  • Hiromu Fukuda,
  • Eiji Kimura,
  • Kentaro Nakagawa,
  • Hirotsugu Saiki,
  • Ryotaro Uema,
  • Takeo Yoshihara,
  • Yoshiki Tsujii,
  • Tetsuo Takehara

摘要

Background

Pathological T1a-muscularis mucosa with lymphovascular invasion and T1b-submucosa are high-risk factors for lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Esophagectomy and chemoradiotherapy are recommended following endoscopic submucosal dissection (ESD) but can lead to complications. Here, we evaluated the efficacy and safety of chemotherapy following ESD.

Methods

This prospective and retrospective study included patients with pathological T1a-muscularis mucosa with lymphovascular invasion or T1b-submucosa who underwent esophageal ESD between June 2006 and August 2023, followed by chemotherapy or chemoradiotherapy. The overall survival, cause-specific survival, recurrence-free survival, hospitalization period, and the occurrence of grade ≥ 3 adverse events were compared between the chemotherapy and chemoradiotherapy groups.

Results

The patient and tumor characteristics and pathological findings did not significantly differ between the chemotherapy (n = 16) and chemoradiotherapy (n = 15) groups. The 5-year overall and recurrence-free survival rates were significantly higher in the chemotherapy group than in the chemoradiotherapy group (100.0% vs. 77.8%, P < 0.001 and 92.3% vs. 84.9%, P = 0.007, respectively; log-rank test). The 5-year cause-specific survival rate did not significantly differ between groups (100.0% vs. 83.3%, P = 0.14, log-rank test). The hospitalization period was significantly shorter in the chemotherapy group than in the chemoradiotherapy group (34 vs. 48 days, P < 0.001). Grade ≥ 3 adverse events occurred in 4 (25.0%) and 11 (73.3%) patients in the chemotherapy and chemoradiotherapy groups, respectively.

Conclusions

Chemotherapy is a safe and effective additional treatment for ESCC (pathological T1a-muscularis mucosa with lymphovascular invasion or T1b-submucosa) after ESD.